Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Neridronate→

Neridronate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
79778-41-9
Molecular formula
C6H17NO7P2
Molecular weight
277.15 g/mol
Drug class
Nitrogen-free bisphosphonateinhibitor of osteoclast-mediated bone resorption
Mechanism of action
Adsorbs to hydroxyapatite in bone and is taken up by osteoclasts, impairing osteoclast function and reducing bone resorption. Unlike nitrogen-containing bisphosphonates, it does not act through farnesyl-pyrophosphate synthase inhibition.
Indications / reported uses
  • Treatment of Paget’s disease of bone and selected metabolic bone disorders, including osteogenesis imperfecta or complex regional pain syndrome in countries where neridronate is authorised.

Sources: https://pubmed.ncbi.nlm.nih.gov/?term=neridronate+pharmacology+indications · https://pubchem.ncbi.nlm.nih.gov/#query=neridronate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Neridronate Environmental Risk Assessment (ERA) (the Neridronate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.